Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Rosacea pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for rosacea. The report also analyzes the clinical and commercial landscapes of rosacea, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Rosacea is a chronic relapsing inflammatory skin disease characterized by immune dysfunction and neurovascular dysregulation. Though its pathophysiologic connections remain to be defined, there are numerous studies showing association of rosacea with chronic inflammatory conditions including inflammatory cytokines and metabolic, immune, and endocrine changes.

Which are the key regions in the Rosacea pipeline drugs market?

The key regions in the Rosacea pipeline drugs market are Asia-Pacific, Europe, Middle Eat & Africa, South & Central America. Single-country trials dominated in rosacea globally over the past 10 years, with highest number of trials registered in North America.

Rosacea pipeline drugs market, by regions

Rosacea pipeline drugs market, by regions

For more region insights, download a free report sample

Which are the key development stages in the Rosacea pipeline drugs market?

The key development stages in the Rosacea pipeline drugs market are phase II, phase III, phase I, and preclinical. Preclinical stage has the highest share in the Rosacea pipeline drugs market.

Rosacea pipeline drugs market, by development stage

Rosacea pipeline drugs market, by development stage

For more development stage insights, download a free report sample

Which are the key molecule types in the Rosacea pipeline drugs market?

The key molecule types in the Rosacea pipeline drugs market are small molecule, and biologic. The majority of drugs with a known molecule type in development for the treatment of rosacea are small molecules.

Rosacea pipeline drugs market, by molecule types

Rosacea pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key MoA in the Rosacea pipeline drugs market?

The key MoA in the Rosacea pipeline drugs market are genes, nucleic acid, & related components inhibitor, enzyme inhibitor, receptor antagonist, receptor inhibitor, cells and cells organelle disrupter, protein and peptide inhibitor. Most of the molecules undergoing development for rosacea with a known mechanism of action are inhibitors of genes, nucleic acids, and related components.

Rosacea pipeline drugs market, by MoA

Rosacea pipeline drugs market, by MoA

For more MoA insights, download a free report sample

Which are the key RoA in the Rosacea pipeline drugs market?

The key RoA in the Rosacea pipeline drugs market are topical, oral, injection, and inhalational. Inhalational has the highest share in the Rosacea pipeline drugs market.

Rosacea pipeline drugs market, by RoA

Rosacea pipeline drugs market, by RoA

For more RoA insights, download a free report sample

Which are the key sponsors in the Rosacea pipeline drugs market?

The key sponsors in the Rosacea pipeline drugs market are Galderma SA, Allergan Ltd, Cutanea Life Sciences Inc, So-Gel Technologies Inc, Foamix Pharmaceuticals Ltd, Amorepacific Corp, Padagis LLC, and others.

Rosacea pipeline drugs market, by sponsors

Rosacea pipeline drugs market, by sponsors

To know more about sponsors, download a free report sample

Market report overview

Key regions Asia-Pacific, Europe, Middle Eat & Africa, South & Central America
Key development stages Phase II, Phase III, Phase I, And Preclinical
Key molecule types Small Molecule, and Biologic
Genes, Nucleic Acid, & Related Components Inhibitor, Enzyme Inhibitor, Receptor Antagonist, Receptor Inhibitor, Cells and Cells Organelle Disrupter, Protein and Peptide Inhibitor
Key RoA Topical, Oral, Injection, and Inhalational
Key sponsors Galderma SA, Allergan Ltd, Cutanea Life Sciences Inc, So-Gel Technologies Inc, Foamix Pharmaceuticals Ltd, Amorepacific Corp, and Padagis LLC

Scope

GlobalData’s Rosacea: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type and Route of Administration
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Rosacea market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Rosacea market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

5 Pipeline Drugs Assessment

5.1 Late-stage Pipeline Drugs

5.2 Overview by Development Stage

5.3 Overview by Molecule Type

5.4 Overview by Mechanism of Action

5.5 Overview by Route of Administration

5.6 Therapy Area and Indication-specific PTSR and LoA

5.7 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6 Clinical Trials Assessment

6.1 Historical Overview

6.2 Overview by Phase

6.3 Overview by Status

6.4 Overview by Phase for Ongoing and Planned Trials

6.5 Trials with Virtual Components

6.6 Geographic Overview

6.7 Single-Country and Multinational Trials by Region

6.8 Top 20 Sponsors with Breakdown by Phase

6.9 Top 20 Sponsors with Breakdown by Status

6.10 Overview by Endpoint Status

6.11 Overview by Race and Ethnicity

6.12 Enrollment Data

6.13 Top 20 countries for Trial Sites

6.14 Top 20 Sites Globally

6.15 Feasibility Analysis – Geographic Overview

6.16 Feasibility Analysis – Benchmark Models

7 Deals Landscape

7.1 Mergers, Acquisitions, and Strategic Alliances by Region

7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

10.1 Methodology

10.2 Methodology – PTSR and LoA Analysis

10.3 About the Authors

10.4 Contact Us

10.5 Disclaimer

Frequently asked questions

Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape standard reports
Currency USD
$3,495

Can be used by individual purchaser only

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape in real time.

  • Access a live Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.